Glepaglutide - Zealand Pharma

Drug Profile

Glepaglutide - Zealand Pharma

Alternative Names: ZP 1848

Latest Information Update: 10 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zealand Pharma
  • Class Anti-inflammatories; Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Short bowel syndrome
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 25 Sep 2018 Phase-III clinical trials in Short bowel syndrome in Poland (SC) (NCT03690206)
  • 16 May 2018 Zealand Pharma plans a phase III trial for Short bowel syndrome in USA, Canada and European Union in the third quarter of 2018
  • 18 Dec 2017 Zealand Pharma completes a phase I trial for Short bowel syndrome (in volunteers) in USA (NCT03279302)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top